TTNP Archives | BioTuesdays

Developments

Titan Pharma Probuphine commercialization partner inks European distribution agreement

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine commercialization partner, Molteni, signed an exclusive European distribution agreement with Accord Healthcare Europe for the commercialization of Sixmo, the brand name...

September 15, 2020

Developments

Titan Pharma and Indegene provide details of new Probuphine co-promotion partnership

Titan Pharmaceuticals’ (NASDAQ:TTNP) CEO, Sunil Bhonsle, and Indegene VP of co-commercialization, Jamie Peck, provided additional information on their recently established Probuphine co-promotion partnership. In an...

July 29, 2020

Developments

Titan Pharma and Indegene sign Probuphine co-promotion partnership

Titan Pharmaceuticals (NASDAQ:TTNP) signed a co-promotion partnership with Indegene to establish multichannel digital marketing programs across the U.S. and engage health care providers (HCPs) who are eligible to...

June 24, 2020

Developments

Titan Pharma’s Probuphine added to Federal Supply Schedule

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, a novel six-month maintenance treatment for opioid use disorder (OUD), will be included on the Federal Supply Schedule (FSS) beginning on January 15, 2020. The...

January 13, 2020

Developments

Kate DeVarney joins Titan Pharma’s Board

Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...

December 30, 2019

Markets

Maxim ups Titan Pharma to buy with PT of $1

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold,” establishing a $1 price target as the company has raised capital and removed a financing overhang. The stock was quoted at 20 cents in...

October 23, 2019

Developments

Titan Pharma to present two Probuphine posters at conference

Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...

October 22, 2019

Developments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...

September 18, 2019

Developments

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Knight Therapeutics (TSX:GUD) reached agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent covering reimbursement of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first...

August 6, 2019

Developments

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Titan Pharmaceuticals (NASDAQ:TTNP) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing authorization of Sixmo, the brand name for...

April 29, 2019

Tag - TTNP

Titan Pharma Probuphine commercialization partner inks European distribution agreement

Titan Pharma and Indegene provide details of new Probuphine co-promotion partnership

Titan Pharma and Indegene sign Probuphine co-promotion partnership

Titan Pharma’s Probuphine added to Federal Supply Schedule

Kate DeVarney joins Titan Pharma’s Board

Maxim ups Titan Pharma to buy with PT of $1

Titan Pharma to present two Probuphine posters at conference

Titan Pharma gets second year of NIDA funding for nalmefene implant development

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter